Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 953-955

  Visalli, Melissa A ^a   Jacobs, Michael R ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFPIROME; CEFTAZIDIME; GENTAMICIN; LEVOFLOXACIN; MEROPENEM;

ANIMAL CELL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CELL KILLING; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG DETERMINATION; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOTE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0031967431     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.953     Document Type: Note

References (20)

1. Bajaksouzian, S., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1996. Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined hy checkerboard and time-kill methods. Antimicrob. Agents Chemother. 40:1973-1976.
2. Bajaksouzian, S., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1997. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies. Antimicrob. Agents Chemother. 41:1073-1076.
3. Burwen, D. R., S. N. Banerjee, R. P. Gaynes, and the National Nosocomial Infections Surveillance System. 1994. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J. Infect. Dis. 170: 1622-1625.
4. Cappelletty, D. M., and M. J. Rybak. 1996. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:677-683.
5. Cheng, A. F. B., T. K. W. Ling, A. W. Lam, K. S. C. Fung, and R. Wise. 1993. The antimicrobial activity and β-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents. J. Antimicrob. Chemother. 31:699-709.
6. Edson, R. S., and C. L. Terrell. 1991. The aminoglycosides. Mayo Clin. Proc. 66:1158-1164.
7. Edwards, J. R. 1995. Meropenem: a microbiological overview. J. Antimicrob. Chemother. 36(Suppl. A):1-17.
8. Eliopoulos, G., and R. C. Moellering, Jr. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.). Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, Md.
9. Fu, K. P., S. C. Lafredo, B. Foleno, D. M. Isaacson, J. F. Barrett, A. J. Tobia, and M. E. Rosenthale. 1992. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
10. Gargalianos, P., B. A. Oppenheim, P. Skepastianos, D. M. Livermore, and R. J. Williams. 1988. Activity of cefpirome (HR 810) against Pseudomonas aeruginosa strains with characterized resistance mechanisms to β-lactam antibiotics. J. Antimicrob. Chemother. 22:841-848.
11. Gerding, D. N., T. A. Larson, R. A. Hughes, M. Weiler, C. Shanholtzer, and L. R. Petersen. 1991. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob. Agents Chemother. 35:1284-1290.
12. Gilligan, P. H. 1995. Pseudomonas and Burkholderia, p. 509-519. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
13. Jones, R. N. 1992. The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Diagn. Microbiol. Infect. Dis. 15: 3S-10S.
14. Jones, R. N., M. A. Pfaller, S. D. Allen, E. H. Gerlach, P. C. Fuchs, and K. E. Aldridge. 1991. Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6,000 recent clinical isolates from five medical centers. Diagn. Microbiol. Infect. Dis. 14:361-364.
15. Levin, S., and P. H. Karakusis. 1986. Future trends in aminoglycoside therapy. Am. J. Med. 80(Suppl. 6B):190-194.
16. Livermore, D. M., and Y. Yang. 1989. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. J. Antimicrob. Chemother. 24(Suppl. A):149-159.
17. Moellering, R. C., Jr., G. M. Eliopoulos, and D. E. Sentochnik. 1989. The carbapenems: new broad-spectrum β-lactam antibiotics. J. Antimicrob. Chemother. 24(Suppl. A):1-7.
18. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS publication no. M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
19. Neu, H. C., and N.-X. Chin. 1989. In vitro activity of S-ofloxacin. Antimicrob. Agents Chemother. 33:1105-1107.
20. Tanaka, M., M. Otsuki, T. Une, and T. Nishino. 1990. In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin. J. Antimicrob. Chemother. 26:659-666.